Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
about
Pathogenesis, management and prevention of atypical femoral fracturesLong-term safety of antiresorptive treatment: bone material, matrix and mineralization aspectsBisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectAtypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and PreventionVibrational spectroscopic imaging for the evaluation of matrix and mineral chemistryTowards the in vivo prediction of fragility fractures with Raman spectroscopySpatial variation in osteonal bone properties relative to tissue and animal age.Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.Histology of 8 atypical femoral fractures: remodeling but no healingAge-related changes in the plasticity and toughness of human cortical bone at multiple length scales.Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual.Studying variations in bone composition at nano-scale resolution: a preliminary report.Aging and bone.Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportPatterns of bisphosphonates utilization in patients under age 45 in a large cohort of commercial insurance beneficiaries in the United StatesInfrared assessment of bone quality: a reviewFourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjectsBone tissue composition varies across anatomic sites in the proximal femur and the iliac crest.Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?Brief mechanical ventilation impacts airway cartilage properties in neonatal lambs.Imaging the material properties of bone specimens using reflection-based infrared microspectroscopy.Quantifying mineralization using bone mineral density distribution in the mandible.Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy.Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture.Images in medicine - bisphosphonate induced atypical fracture.A Case Report of Bisphosphonate-induced Bilateral Osteoporotic Subtrochanteric Fracture Femurii: Review of Literature.Compressive loading of the murine tibia reveals site-specific micro-scale differences in adaptation and maturation rates of bone."Atypical" atypical femur fractures and use of bisphosphonates.Bisphosphonates and atypical subtrochanteric fractures of the femur.Bone mineralization: from tissue to crystal in normal and pathological contexts.Novel assessment tools for osteoporosis diagnosis and treatment.Changes in the degree of mineralization with osteoporosis and its treatment.Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports.Bone's Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment.
P2860
Q26824555-694F7325-B26B-4EC7-8EFE-A7F2B137ED5CQ27025945-0447ED97-64D9-4EA2-89A1-E4EEB29366B7Q27026618-F787FB8F-BC2B-441F-9E37-347AE81A0046Q28079133-131AA3F3-898C-4F7A-9664-E0567E7F2F94Q28393488-8B6D5670-6EA1-4724-B6BF-F9E654F6F014Q28831147-A92EB83D-6921-4CF6-B9AF-0D3F35BC9953Q33408274-8E6B78C9-1E60-4BFC-9D51-605F641D0F66Q33557256-E827EDC0-A171-438B-909E-F6EA90333750Q33665130-C6EA996D-3941-4FD6-8869-3F226064DFE2Q33774987-60CB3EAB-62BE-4957-9F44-83907F47DCFDQ34004460-00AB9527-0182-4849-80F9-DFE23835554AQ34048762-B15C0E77-04EE-45E6-B006-EFB9D92B3B38Q34315823-88DC8651-4B65-4851-A679-32CBA9137FACQ34348145-ECF0D2F3-F3E3-4D56-AC3F-84F4DE7296CBQ34486831-4ABAF416-8957-41BC-B793-44D75A183146Q35001586-B6B32E09-7C83-421F-8CD2-C6896C469F9DQ35078785-B06C08D7-BBD2-41CE-9BD2-9CDAAB9FB1D1Q35226570-DACCDB0B-D554-40C9-BFA8-5C6A660E9D99Q35505244-953CBCD4-B2C0-47EB-A367-E8BD8052C99FQ35566438-37E14E5C-9A4C-4A8B-AA86-1C9D83BC5F52Q35751806-A433B1E6-CB6F-4726-85BE-17B1C9954410Q35807492-9E4AA67F-5263-4222-A420-1E437D6E4CABQ35996047-8A741D62-64BC-400B-99EB-4BD60DFBE262Q35999527-BEAB21E0-DD64-45FF-9D67-28DCAE2E1B1FQ36546728-49532905-355D-43CD-9FFB-8BF6F6BBB524Q36633388-D944AE93-E591-4863-A1E4-DFCE36A58B22Q36729340-43918A42-3846-474A-8FC1-2199FCA22C0FQ36889362-E2D26A82-713D-4291-A18F-19019849A308Q37237676-8CF5F16E-B38D-4232-A345-E88D87510899Q37315942-0E09C468-057E-4F45-BA83-F0ECDDE7E079Q37612002-17AA93D3-64F8-469A-8033-D1CA80F6EC36Q37620378-FCE85D70-55C8-41AD-9C09-981D843E2DE5Q37639355-341D41F5-CC5B-4415-9004-DAB214531EAAQ37653262-2A3BC746-CA36-4BA8-AA86-C9CC3FAA7DB8Q37733851-81199353-D913-43F4-AEA3-293AE99BC87EQ38066387-C6B04283-41F5-47B0-8E41-DBD28EFC8EB6Q38216229-021C5621-4947-4717-9A40-FAA21151AEAEQ38221766-FFFD7EEF-F839-4D03-B80E-AAB9067617A7Q38250224-807C35A4-5B37-43D5-BA4F-0D87FF19936DQ38364893-AA2E494B-B140-474B-9BE9-F37F5FE10853
P2860
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
@en
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.
@nl
type
label
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
@en
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.
@nl
prefLabel
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
@en
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.
@nl
P2860
P1476
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
@en
P2093
R S Weinstein
P2860
P2888
P304
P356
10.1007/S00198-008-0725-9
P407
P577
2008-09-04T00:00:00Z